Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Japan's Takeda plans to sell consumer health unit for around $3.7 bln - Nikkei (updated)

(Adds Taisho Pharma no comment in second paragraph; Takeda
share move, background)
    TOKYO, April 24 (Reuters) - Japan's Takeda Pharmaceutical Co
Ltd  4502.T  plans to sell its consumer health unit for around
400 billion yen ($3.72 billion), Nikkei Business reported.
    Possible buyers of Takeda Consumer Healthcare Co include
Taisho Pharmaceutical Co.  4581.T  and large investment funds,
Nikkei reported. Spokespeople for both Takeda and Taisho
declined to comment.
    Takeda Chief Executive Christophe Weber said last year that
a sale of the Japan-focused consumer unit, known for its
Alinamin line of energy drinks, was unlikely.
    Japan's biggest pharma company would focus on overseas
divestitures in its pledge to sell $10 billion of assets to
reduce debt in the wake of the $59 billion purchase of Shire
Plc, Weber said at the time.
    It completed $7 billion of divestments in calendar 2019,
including assets in the Middle East and Africa and a dry-eye
drug sold for $5.3 billion to Novartis  NOVN.S , Refinitiv data
show. 
    Takeda is due to report full-year earnings on May 13. Its
shares rose 2.5% in Tokyo trading versus a 0.8% drop in the
broader market  .N225 . Takeda shares are still down more than
12% so far this year.
($1 = 107.6500 yen)

 (Reporting by Rocky Swift; Editing by Muralikumar Anantharaman)
 ((rocky.swift@thomsonreuters.com;))

Recent news on Taisho Pharmaceutical Holdings Co

See all news